Pompton Lakes, NJ, United States of America

Jianhua Chao

This inventor holds 20 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 9 EPO patents. Top assignees: Schering Corporation, Merck Sharp + Dohme Corp., Pharmacopeia Drug Discovery, Inc.. Active years: 2005-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jianhua Chao. Retrieved from https://idiyas.com/inventor/jianhua-chao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 7)

% Patents Active = 15.0

CIPO Patents = 1

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 81(Granted Patents)

Location History:

Pompton Lakes, NJ (US) (2005 - 2013)
San Diego, CA (US) (2012 - 2013)
Cambridge, MA (US) (2016 - 2019)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

5 out of 52

Pharmacopeia Drug Discovery, Inc.

Schering-Plough Corporation

patents

where one patent can have more than one assignee

Years Active: 2005-2019

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10399924 - Deuterium substituted fumarate derivatives (2019-09-03),

2. 9850206 - S1P and/or ATX modulating agents (2017-12-26),

3. 9421273 - Silicon-containing fumaric acid esters (2016-08-23),

4. 8569312 - Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators (2013-10-29),

5. 8476274 - Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators (2013-07-02),

6. 8470863 - Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists (2013-06-25),

7. 8383818 - Functionally selective alpha2C adrenoreceptor agonists (2013-02-26),

8. 8324213 - Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators (2012-12-04),

9. 7964646 - 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands (2011-06-21),

10. 7960433 - Treatment of chemokine mediated diseases (2011-06-14),

11. 7947720 - 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands (2011-05-24),

12. 7846946 - [object Object] (2010-12-07),

13. 7786149 - Thiadiazoles as CXC- and CC- chemokine receptor ligands (2010-08-31),

14. 7691856 - Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands (2010-04-06),

15. 7671212 - Isothiazole dioxides as CXC- and CC-chemokine receptor ligands (2010-03-02),

Title: Innovations and Contributions of Jianhua Chao in Pharmaceutical Patents

Introduction: Jianhua Chao, residing in Pompton Lakes, NJ, has made significant contributions to the pharmaceutical industry, holding an impressive portfolio of 20 patents. His work primarily focuses on the development of novel pharmaceutical compositions and methods for treating various diseases, particularly neurodegenerative conditions.

Latest Patents: Among Jianhua Chao's latest patents are innovative compounds such as deuterium substituted fumarate derivatives. These derivatives are designed for pharmaceutical compositions aimed at treating or ameliorating diseases like multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, and Alzheimer's disease. Another notable innovation involves S1P and ATX modulating agents, which encompass a range of compounds capable of modulating the activity of sphingosine-1-phosphate receptors and autotaxin, potentially offering new therapeutic avenues for various conditions.

Career Highlights: Jianhua Chao has built an impressive career, marked by significant roles at reputable organizations such as Schering Corporation and Pharmacopeia Drug Discovery, Inc. His expertise in drug discovery and development has paved the way for advancements in treatment methodologies and therapeutic compositions.

Collaborations: Throughout his career, Jianhua has collaborated with notable colleagues, including Younong Yu and Arthur G. Taveras. These partnerships have enriched his research and have significantly contributed to the innovations he has developed, reflecting the power of teamwork in driving forward pharmaceutical discoveries.

Conclusion: Jianhua Chao's contributions to the field of pharmaceuticals through his patents underscore his inventive spirit and dedication to improving therapeutic interventions. His work not only reflects the importance of innovation in tackling complex health challenges but also serves as an inspiration for future inventors in the realm of drug development.

Profile summary based on public USPTO records.